Wegovy Weight Loss Injection
You can request to buy Wegovy online from Simple Online Pharmacy later in 2022. Wegovy contains the active ingredient semaglutide and is prescribed for adults with obesity. It has recently been approved for use in the UK and will be available later this year. It was approved in the USA in 2021.
Our UK clinical team and pharmacy are working closely with Novo Nordisk to ensure we are ready to prescribe Wegovy UK safely as soon as it becomes available. Other weight loss treatments like Saxenda and Orlistat are currently available from our online doctor weight loss clinic.
What is Wegovy?
Wegovy Weight Loss Injection. Wegovy is a weight loss injection that can be an effective weight-loss aid when used alongside a reduced-calorie diet and increased exercise. The weight loss drug contains the active ingredient semaglutide. The medicine is injected once a week and can be used by adults with a body mass index (BMI) over 30. It can also be used by people with a BMI over 27 with weight-related conditions (such as high blood pressure or type 2 diabetes).
The active ingredient, semaglutide, is currently licensed i as a type 2 diabetes treatment under the brand name Ozempic. Ozempic isn’t licensed as a weight loss medication , but Wegovy is licensed for weight loss with a specific weight loss dosing and formulation.
How does Wegovy work?
The active ingredient, semaglutide, is a type of medicine called a GLP-1 receptor agonist. This means it mimics a hormone produced by the body called glucagon like peptide 1 (GLP-1). This hormone plays an important role in regulating appetite (the feeling of fullness).
By mimicking this hormone, Wegovy acts on receptors in the brain that control your appetite. It causes you to feel fuller and less hungry, leading to less craving for food. This can help you eat less and cause you to lose weight.
Is Wegovy effective for weight loss?
Clinical trials have shown that Wegovy treatment resulted in a statistically significant reduction in body weight compared to placebo after 68 weeks. One trial showed that people taking Wegovy had a mean change in body weight of 14.9% compared to 2.4% in the placebo group.
The results also showed that, after 68 weeks, 83.5% of patients lost 5% or more of their body weight. In the placebo group, 31.1% of patients lost 5% or more of their body weight. Another clinical trial also showed a statistically significant reduction in body weight vs placebo.
The National Institute for Health and Care Excellence (NICE) has recommended Wegovy for those living with obesity due to the highly positive trial results.
Wegovy vs Placebo Trial Results
% of Patients Achieving Different Percentages of Weight Loss.
How to take Wegovy
The Wegovy dose is increased every 4 weeks for 16 weeks. This means that patients take a 0.25mg once weekly dose for the first 4 weeks and gradually increase it until they reach the maintenance dose of 2.4 mg once weekly from week 17 onwards. This gradual increase is important because it minimises the risk of side effects. If side effects do occur, most will be experienced during the dose-escalation phase before improving.
Wegovy (semaglutide) should be injected once a week on the same day each week. It can be taken at any time of day and can be taken with or without meals. It should be injected subcutaneously into the abdomen, thigh or upper arm.
Inject ONCE weekly, following the dose-escalation schedule
|Type of medicine||
Appetite-suppressant – GLP-1 receptor agonist
Suppresses appetite and promotes feeling full for longer, decreasing food intake.
Lowest online – To be announced
Can include nausea, diarrhoea, constipation, abdominal pain, vomiting
Saxenda is the closest medicine to Wegovy working in the same way and being is manufactured by the same company, Novo Nordisk. Saxenda is injected once daily into the abdomen, thigh or upper arm.
You can visit our online doctor weight loss clinic to see what weight loss options are available to you.
Wegovy Side Effects
Like with all medicines, some people may experience side effects from the treatment. Not everyone will get them and a majority will be mild. Only 5.3% of patients in one clinical trial stopped Wegovy due to side effects.